表 1.
LCNEC相关免疫治疗回顾性研究及临床研究
ICIs related retrospective study and clinical trial for LCNEC
| Research | Phase | n | Drugs | ORR | mPFS (mon) | mOS (mon) | Identifier |
| LCNEC: large cell neuroendocrine carcinoma; ICIs: immune checkpoint inhibitors; ORR: objective response rate; mPFS: median progression-free survival; mOS: median overall survival; nivo: Nivolumab; pem: Pembrolizumab; ipi: Ipilimumab; *: non-LCNEC group; mon: month. | |||||||
| Matteo et al[27] | Retrospective | 10 | pem or nivo | 60% | 13.3 | ||
| Shira et al[28] | Retrospective | 21 vs 270* | ICIs | 33% | 4.2 | 11.8 vs 6.9* | |
| DART SWOG 1609[33] | II | 32 | ipi+nivo | 25% | 4.0 | 11.0 | NCT02834013 |